The present invention relates in general to a stable, preferably liquid, pharmaceutical formulation comprising an antibody, a buffer, a surfactant, a stabilizer selected from the group consisting of sugars and sugar alcohols, and further optionally a chelator and/or oxygen-scavenger. Furthermore, the present invention relates to an article of manufacture comprising a container and a stable pharmaceutical formulation of the invention.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
The present invention relates in general to a stable, preferably liquid, pharmaceutical formulation comprising an antibody, a buffer, a surfactant, a stabilizer selected from the group consisting of sugars and sugar alcohols, and further optionally a chelator and/or oxygen-scavenger. Furthermore, the present invention relates to an article of manufacture comprising a container and a stable pharmaceutical formulation of the invention.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
3.
GLYCOPROTEIN WITH REDUCED ACETYLATION RATE OF SIALIC ACID RESIDUES
The present invention relates to a method or process of producing a glycoprotein that interacts with, or acts as an agonist to, the erythropoietin receptor (EpoR), which glycoprotein has modified efficacy, wherein the method or process comprises the heterologous expression of said glycoprotein in a suitable expression system, and wherein at least one step is provided that results in a reduced acetylation rate of sialic acid residues in the glycoprotein (FIG. 16).
The present invention discloses an immediate release tablet comprising at least a tablet core, wherein the tablet core comprises at most 20% brexpiprazole relative to the total of the tablet core, and at least one pharmaceutically acceptable excipient, wherein the tablet core is made by direct compression. Also disclosed are a batch of such immediate release tablets, and a process for preparing such immediate release tablets.
The present invention relates to the field of biotechnology, and in particular to the field of antibodies. Provided herein are novel methods for removing glycosylated antibody variants from an antibody preparation, an antibody preparation obtained by said method, and a pharmaceutical composition comprising the same.
The present invention relates to crystalline brexpiprazole having a particle size distribution (PSD) characterized by a d(90) of 30 μm to 100 μm, by a d(10) of at least 1.0 μm, and by a d(4,3) of at least 15.0 μm. The present invention also relates to a pharmaceutical composition comprising a crystalline brexpiprazole having a PSD characterized by a d(90) of 30 μm to 100 μm, by a d(10) of at least 1.0 μm, and by a d(4,3) of at least 15.0 μm, and to an aqueous suspension comprising said crystalline brexpiprazole. The present invention also relates to a composition comprising a crystalline brexpiprazole having a PSD characterized by a d(90) of 30 μm to 100 μm, by a d(10) of at least 1.0 μm, and by a d(4,3) of at least 15.0 μm, wherein said composition is essentially free from secondary particles of brexpiprazole. The present invention also relates to an injectable preparation, vial, prefilled syringe, or kit, comprising crystalline brexpiprazole having a PSD characterized by a d(90) of 30 μm to 100 μm, by a d(10) of at least 1.0 μm, and by a d(4,3) of at least 15.0 μm. The present invention also relates to a process for the preparation of an aqueous suspension, a vial, a prefilled syringe, or a lyophilisate, comprising a step of incorporating crystalline brexpiprazole having a PSD characterized by a d(90) of 30 μm to 100 μm, by a d(10) of at least 1.0 μm, and by a d(4,3) of at least 15.0 μm. Finally, the present invention also relates to crystalline brexpiprazole having a PSD characterized by a d(90) of 30 μm to 100 μm, by a d(10) of at least 1.0 μm, and by a d(4,3) of at least 15.0 μm, for use in the treatment or prevention of relapse of schizophrenia, bipolar disorder, or depression.
C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
The present invention relates to pharmaceutical compositions comprising obeticholic acid, a pharmaceutically acceptable salt, solvate, solvated salt or amino acid conjugate thereof in dissolved form, processes for preparing the pharmaceutical compositions, and their use in the treatment of FXR-mediated diseases.
A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
The present invention relates to a brexpiprazole dihydrate crystalline form having a particle size distribution of d50 of at most 10 μm and less than 5% w/w of brexpiprazole anhydrate. The present invention also relates to a process for preparing this brexpiprazole dihydrate crystalline form and to pharmaceutical compositions thereof. The present invention also relates to a process for determining the absence of brexpiprazole anhydrate in this brexpiprazole dihydrate crystalline form. This brexpiprazole dihydrate crystalline form is used for the preparation of pharmaceutical compositions having delayed release properties upon intramuscular injection.
C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
The present invention relates to a composition comprising tenofovir alafenamide, a stabilizing agent, preferably an earth alkali salt and/or silicon dioxide, and a pharmaceutical excipient. Further, the invention relates to a method of preparing said composition. The pharmaceutical compositions of the present invention can be used for the treatment and/or prophylaxis of viral infections such as HIV infections.
The present invention relates to crystalline brexpiprazole having a particle size distribution (PSD) characterized by a d(90) of 30 μm to 100 μm, by a d(10) of at least 1.0 μm, and by a d(4,3) of at least 15.0 μm. The present invention also relates to a pharmaceutical composition comprising a crystalline brexpiprazole having a PSD characterized by a d(90) of 30 μm to 100 μm, by a d(10) of at least 1.0 μm, and by a d(4,3) of at least 15.0 μm, and to an aqueous suspension comprising said crystalline brexpiprazole. The present invention also relates to a composition comprising a crystalline brexpiprazole having a PSD characterized by a d(90) of 30 μm to 100 μm, by a d(10) of at least 1.0 μm, and by a d(4,3) of at least 15.0 μm, wherein said composition is essentially free from secondary particles of brexpiprazole. The present invention also relates to an injectable preparation, vial, prefilled syringe, or kit, comprising crystalline brexpiprazole having a PSD characterized by a d(90) of 30 μm to 100 μm, by a d(10) of at least 1.0 μm, and by a d(4,3) of at least 15.0 μm. The present invention also relates to a process for the preparation of an aqueous suspension, a vial, a prefilled syringe, or a lyophilisate, comprising a step of incorporating crystalline brexpiprazole having a PSD characterized by a d(90) of 30 μm to 100 μm, by a d(10) of at least 1.0 μm, and by a d(4,3) of at least 15.0 μm. Finally, the present invention also relates to crystalline brexpiprazole having a PSD characterized by a d(90) of 30 μm to 100 μm, by a d(10) of at least 1.0 μm, and by a d(4,3) of at least 15.0 μm, for use in the treatment or prevention of relapse of schizophrenia, bipolar disorder, or depression.
C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
The present invention relates to the field of biotechnology, and in particular to the field of antibodies. Provided herein are novel methods for removing glycosylated antibody variants from an antibody preparation, an antibody preparation obtained by said method, and a pharmaceutical composition comprising the same.
The present invention relates to an enteric-coated tablet comprising vortioxetine or a pharmaceutically acceptable salt thereof as an active pharmaceutical ingredient (API), the API having a particle size distribution of D90 of 100 μm or less. Furthermore, the invention relates to a process of manufacturing said tablet.
The present invention discloses possibilities to make use of a substance or a material arranged to block, absorb and/or reflect UV exposure of a certain wavelength region to reduce or prevent UV-induced dimerization and optionally further UV-induced brexpiprazole impurities of brexpiprazole in a brexpiprazole dihydrate comprising pharmaceutical composition.
The present invention is directed to a pharmaceutical dosage form exhibiting improved stabilization of an angiotensin-converting-enzyme inhibitor (ACE inhibitor) present therein. The dosage form comprises the angiotensin-converting-enzyme inhibitor and a stabilizer and has at least two separate portions, wherein the angiotensin-converting-enzyme inhibitor is contained in one of the portions and the stabilizer compound is contained in another portion. The dosage form can make use of an intra- granular/extra-granular structure, wherein preferably the ACE inhibitor compound is placed within the intra-granular portion and the stabilizer is placed in the extra-granular portion, or vice versa the stabilizer is placed within the intra-granular portion and the ACE inhibitor compound is placed in the extra-granular portion, and further alternatively when adopting a core/shell structure, such that the ACE inhibitor is contained in the core and the stabilizer compound is contained in a surrounding layer, or the ACE inhibitor is contained in a surrounding layer and the stabilizer compound is contained in the core, wherein optionally an intermediate layer, such as a layer basically formed from a film-forming polymer, can be provided between the core and the surrounding layer.
The present invention relates to a method or process of producing a glycoprotein that interacts with, or acts as an agonist to, the erythropoietin receptor (EpoR), which glycoprotein has modified efficacy, wherein the method or process comprises the heterologous expression of said glycoprotein in a suitable expression system, and wherein at least one step is provided that results in a reduced acetylation rate of sialic acid residues in the glycoprotein (Fig. 16).
The present invention relates to a method for determining the disintegration time of a film-shaped pharmaceutical dosage form and a disintegration testing device for use in such a method.
The present invention relates to a brexpiprazole dihydrate crystalline form having a particle size distribution of d50 of at most 10 µm and less than 5% w/w of brexpiprazole anhydrate. The present invention also relates to a process for preparing this brexpiprazole dihydrate crystalline form and to pharmaceutical compositions thereof. The present invention also relates to a process for determining the absence of brexpiprazole anhydrate in this brexpiprazole dihydrate crystalline form. This brexpiprazole dihydrate crystalline form is used for the preparation of pharmaceutical compositions having delayed release properties upon intramuscular injection.
C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
The present invention relates to a method for analysing protein variants of a recombinant protein of interest, such as antibodies or Fc-fusion proteins, in a liquid sample of a mammal. Specifically the method comprises a step of affinity purifying the recombinant protein of interest from the sample together with an internal standard, and analyzing the protein variants using an analytic separating method such as HPLC, capillary electrophoresis or MS. This method is particularly suited to measure pharmacokinetic parameters of a recombinant protein of interest, such as a biopharmaceutical, in a mammal in clinical or pre-clinical studies. It allows for the use of a small sample volume and the possibility to operate with high throughput, such as in a 96-well plate sample preparation. It also provides high sensitivity and allows analysis of protein variants individually.
A solid composition comprising suvorexant (an orexin receptor antagonist) or a salt thereof and at least one pharmaceutically acceptable compound having an increased specific surface area.
A61K 31/00 - Medicinal preparations containing organic active ingredients
20.
PHARMACEUTICAL COMPOSITION CONTAINING 8-[(3R)-3-AMINO-1-PIPERIDINYL]-7-(2-BUTYN-1-YL)-3,7-DIHYDRO-3-METHYL-1-[4-METHYL-2-QUINAZOLINYL)METHYL]-1H-PURINE-2,6-DIONE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
The present invention relates to a pharmaceutical composition comprising linagliptin or a pharmaceutically acceptable salt thereof as active ingredient, wherein the pharmaceutical composition does not comprise a binder and wherein the pharmaceutical composition is obtained by direct compression.
A liquid composition comprising Suvorexant or a salt thereof, dissolved in one or more sol¬ vents, wherein at least one solvent (N) is liquid at a temperature in the range of from 40 to 50 °C and an absolute pressure in the range of from 40 to 60 mbar.
A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
The present invention relates to an immediate-release solid pharmaceutical composition for oral administration containing ivabradine oxalate, and furthermore, to the use of an antioxidant for preventing chemical degradation of ivabradine oxalate in a solid pharmaceutical composition.
The invention relates to a pharmaceutical film formulation comprising one or more bitter-tasting drug(s) or pharmaceutically acceptable salts thereof, one or more film formers, a bitterness masker containing one or more inorganic and/or organic salt(s) and at least two monocyclic monoterpenes, and one or more sweetening agents.
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61K 47/08 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 47/06 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
A61K 31/4045 - Indole-alkylaminesAmides thereof, e.g. serotonin, melatonin
The present invention relates to pharmaceutical compositions comprising amorphous compound (I) - odanacatib free base -, and a pharmaceutically acceptable inert matrix, wherein odanacatib free base remains in the amorphous state upon storage.
Method for determining the disintegration time of a film-shaped pharmaceutical dosage form and a disintegration testing device for use in such a method.
The present invention relates to orodispersible films comprising a plant extract and to film forming suspensions comprising a plant extract. Further, the present invention relates to processes for preparing the orodispersible films and the film forming suspensions.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 36/00 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
27.
IMPROVED METHOD OF MAPPING GLYCANS OF GLYCOPROTEINS IN SERUM SAMPLES
The present invention relates to a method for analyzing glycans of a recombinant glycoprotein in a liquid sample of a mammal. Specifically the method comprises a step of affinity purifying the recombinant glycoprotein from the sample, enzymatically releasing a glycan containing fragment from the immobilized glycoprotein, adding a reference standard containing isotopically labeled glycans, fluorescently label the glycans and analyzing the glycans using LC-MS. The present invention also relates to a method further comprising analyzing the glycans of the immobilized recombinant glycoprotein fragment, further comprising a pre-clearing step of the liquid sample, and releasing the glycans from the immobilized recombinant glycoprotein fragment. The methods allow for the use of a small sample volume and the possibility to operate with high throughput, such as in a 96-well plate sample preparation and are therefore suited to measure pharmacodynamics parameters of a recombinant glycoprotein in a mammal in clinical or pre-clinical studies.
The present invention relates to pharmaceutical compositions, in particular, it relates to orodispersible films comprising an active pharmaceutical ingredient having a solubility of less than 10 mg/ml in water at RTP and a surfactant 1) having a solubility greater than 30 mg/ml in water at RTP and 2) having a solubility greater than 5 mg/ml in ethanol at RTP. The present invention further relates to film forming suspensions and to processes for preparing the orodispersible films and the film forming suspensions.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
The present invention relates to a pharmaceutical composition which comprises buprenorphine in the form of particles having a maximum particle diameter Dv90 of at most 20 micrometer, and the process of preparation thereof.
A61K 31/485 - Morphinan derivatives, e.g. morphine, codeine
30.
METHOD FOR MANUFACTURING AN INGESTIBLE FILM, APPARATUS FOR MANUFACTURING AN INGESTIBLE FILM, INGESTIBLE FILM AND PHARMACEUTICAL DOSAGE FORM COMPRISING THE SAME
The present invention relates to a method for manufacturing an ingestible film, an apparatus for manufacturing an ingestible film, an ingestible film and a pharmaceutical dosage form comprising the same. The method comprises providing a matrix comprising at least a solvent and a polymer; a film forming step of forming a wet film from said matrix; a heating step of heating said wet film by radiation originating from a radiation source to obtain a heated wet film having a temperature of at least 22°C; and a drying step of drying said heated wet film using a drying means.
The present invention is related to methods of preparing a pharmaceutical formulation comprising a biopharmaceutical drug, which methods allows the modulation of immune responses related to the administration thereof. The formulation comprises a buffer comprising hexanedioic acid or at least one salt thereof, and/or citric acid or at least one salt thereof. The present invention further relates to method of using hexanedioic acid or at least one salt thereof, and/or citric acid or at least one salt thereof, to modulate the immunogenicity of a pharmaceutical formulation, to a pharmaceutical formulation as such, and to methods of modulating or determining immune responses related to the administration of a pharmaceutical formulation (Fig. 4).
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
The invention relates to a pharmaceutical composition, comprising or consisting of: 10 to 30 weight percent of at least a pharmaceutically active amount of a pharmaceutical substance selected from the group comprising statins, in particular water-insoluble, oxidatively degradable statins, preferably cerivastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, simvastatin, or combinations thereof, 30 to 70 weight percent of lactose hydrate, 2 to 15 weight percent of microcrystalline cellulose, 5 to 25 weight percent of a partially water-soluble starch, 0.2 to 4 weight percent of at least one alkali and/or alkaline-earth salt of stearic acid and/or stearyl fumaric acid, wherein the composition contains no antioxidatively active substances such as chain terminators, reductants, free-radical scavengers, and complexing agents. The invention further relates to a method for the production thereof, to a composition that can be obtained in the method, and to the use of the pharmaceutical composition according to the invention.
A61K 31/22 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
A61K 31/405 - Indole-alkanecarboxylic acidsDerivatives thereof, e.g. tryptophan, indomethacin
The present invention relates to a method of producing syringes. Said method comprises fixing a needle to a syringe body by use of an adhesive followed by subjecting the syringes thus obtained to heat treatment. The invention further relates to a method of reducing leachables and/or extractables in prefilled syringes, said method comprising heat treating pre-fabricated syringes at a temperature of at least 40° C. before filling.
A61M 5/34 - Constructions for connecting the needle
B65B 3/00 - Packaging plastic material, semiliquids, liquids or mixed solids and liquids, in individual containers or receptacles, e.g. bags, sacks, boxes, cartons, cans or jars
B65B 55/14 - Sterilising contents prior to, or during, packaging by heat
34.
Methods for preparing an active TNFR-Fc fusion protein
The present invention relates to a method for separating and preparing a TNFR-Fc fusion protein using hydrophobic interaction chromatography (HIC). More particularly, the present invention relates to a method for separating and preparing a highly pure active protein from clipped proteins due to displacement effect by adjusting the conductivity of a protein sample using a high concentration of salt solution and by adjusting a loading amount thereof, and a TNFR-Fc fusion protein prepared by the method.
C07K 14/715 - ReceptorsCell surface antigensCell surface determinants for cytokinesReceptorsCell surface antigensCell surface determinants for lymphokinesReceptorsCell surface antigensCell surface determinants for interferons
35.
PHARMACEUTICAL COMPOSITION COMPRISING N-[3-CHLORO-4-(3-FLUOROBENZYLOXY)PHENYL]-6-[5({[2-(METHYLSULFONYL)ETHYL]AMINO}METHYL)-2-FURYL]QUINAZOLIN-4-AMINE OR A PHARMACEUTICALLY ACCEPTABLE SALT, SOLVATE OR SOLVATED SALT THEREOF
The present invention relates to a pharmaceutical composition comprising N-[3-chloro-4-(3-fluorobenzyloxy)phenyl]-6-[5({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]quinazolin-4-amine or a pharmaceutically acceptable salt, solvate or solvated salt thereof, and a process for preparing the pharmaceutical composition.
The invention relates to a pharmaceutical composition for oral administration comprising or consisting of (i) 10 to 30% weight, of at least one pharmaceutically active substance selected from the group consisting of water-soluble, oxidatively-degradable statins, preferably atorvastatin, cerivastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, simvastatin or a combination thereof, (ii) 0.01 to 3% weight, of a first anti-oxidatively active substance (A1), (iii) 0.01 to 3% weight, of a second anti-oxidatively active substance (A2) that differs from the first anti-oxidatively active substance (A1), and (iv) 60 to 85% weight of at least one additive, selected from the group consisting of filler, binder, flow-regulating agent, disintegrant and anti-blocking agent or a combination thereof, and the use of the pharmaceutical composition in medicine.
03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Soaps; perfumes; essential oils; cosmetics; hair lotions; dentifrices. Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use; food supplements adapted for medical use; food for babies; preparations comprising vitamins, enzymes, minerals and/or trace elements; plasters, materials for dressings; disinfectants; diagnostic preparations and test kits consisting of reagents, anti-serums, or for diagnostic testing material for pharmaceutical, medical and veterinary use; preparations for a medico-diagnostic analysis manufactured through biological methods and/or methods of genetic engineering; medical products as far as contained in class 5. Surgical, medical, dental or veterinary apparatus and instruments; prostheses, artificial limbs, eyes and teeth; orthopedic articles; surgical suture materials; medical products as far as contained in class 10. Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services.
The present invention relates to an oral pharmaceutical composition comprising dabigatran etexilate or a pharmaceutically acceptable salt thereof, methods for preparing it and dosage forms for oral administration comprising said composition. The pharmaceutical composition is particularly useful as a medicament, especially as anticoagulant.
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
39.
IMPROVED METHOD OF MAPPING GLYCANS OF GLYCOPROTEINS
The present invention uses anthranilic acid (2-AA) to label N-glycans prior to separation using a reversed-phase liquid chromatography (RP-LC) column under acidic conditions using formic acid. Negatively charged 2-AA offers stronger retention on the reversed phase column than 2-aminobenzamide (2-AB) in RP-LC and allows efficient ionization and detection of 2-AA labeled N-glycans. The acidic conditions used for the RP-LC leads to an efficient separation of acidic 2-AA N-glycans carrying terminal sialylation without the need for an ion-pairing reagent. The present invention may be used with RP-nano-LC-MS and a 96-well plate sample preparation, which allows attomolar sensitivity and high throughput.
The present invention is related to a pharmaceutical formulation comprising a biopharmaceutical drug, said composition further comprising at least one mono- or dicarboxylic acid with a backbone of 2-6 C-Atoms, or at least one salt thereof.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 9/19 - Particulate form, e.g. powders lyophilised
41.
Transdermal therapeutic system comprising buprenorphine
The invention is concerned with a transdermal therapeutic system (TTS) comprising buprenorphine and a method of manufacturing such a TTS. The transdermal therapeutic system is used for the transdermal administration of buprenorphine and analogues thereof. In particular, the invention relates to the use of a transdermal therapeutic system (TTS) for analgesic purposes. The TTS according to the invention comprises a transdermal drug delivery composition comprising buprenorphine and an adhesive component, which is a mixture of a crosslinked and a non-crosslinked acrylic polymer and a penetration enhancer comprising a keto acid.
The present invention relates to a sustained-release pharmaceutical formulation, in particular a multiple unit pellet tablet (MUT) formulation for oral administration comprising a plurality of sustained-release pellets. The invention further relates to sustained-release pellets wherein the active agent is an opioid. The sustained-release pellets are suitable for the preparation of a multiple unit pellet tablet formulation.
The invention relates to a pharmaceutical composition, comprising or consisting of: 10 to 30 weight percent of at least a pharmaceutically active amount of a pharmaceutical substance selected from the group comprising statins, in particular water-insoluble, oxidatively degradable statins, preferably cerivastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, simvastatin, or combinations thereof, 30 to 70 weight percent of lactose hydrate, 2 to 15 weight percent of microcrystalline cellulose, 5 to 25 weight percent of a partially water-soluble starch, 0.2 to 4 weight percent of at least one alkali and/or alkaline-earth salt of stearic acid and/or stearyl fumaric acid, wherein the composition contains no antioxidatively active substances such as chain terminators, reductants, free-radical scavengers, and complexing agents. The invention further relates to a method for the production thereof, to a composition that can be obtained in the method, and to the use of the pharmaceutical composition according to the invention.
A61K 31/22 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
A61K 31/366 - Lactones having six-membered rings, e.g. delta-lactones
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
A61K 31/405 - Indole-alkanecarboxylic acidsDerivatives thereof, e.g. tryptophan, indomethacin
The present invention relates to a compressed pharmaceutical dosage form intended for sublingual or buccal administration and capable of being rapidly disintegrated, the compressed pharmaceutical dosage form containing asenapine maleate in a microcrystalline monoclinic form. It further relates to a method of preparing the same and to a container comprising the dosage form.
A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
The invention relates to a method for producing a polymorphic form IV of raltegravir potassium. The method is characterized in that raltegravir potassium, as the starting material, is hydrated, said starting material being brought into contact with at least one fluid comprising water during a reaction time, whereby the starting material is hydrated.
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
The invention relates to a pharmaceutical composition for oral administration comprising or consisting of (i) 10 to 30 % weight, of at least one pharmaceutically active substance selected from the group consisting of water-soluble, oxidatively-degradable statins, preferably atorvastatin, cerivastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, simvastatin or a combination thereof,(ii) 0.01 to 3 % weight, of a first anti-oxidatively active substance (A1), (iii) 0.01 to 3 % weight, of a second anti-oxidatively active substance (A2) that differs from the first anti-oxidatively active substance (A1), and (iv) 60 to 85 % weight of at least one additive, selected from the group consisting of filler, binder, flow- regulating agent, disintegrant and anti-blocking agent or a combination thereof, and the use of the pharmaceutical composition in medicine.
A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
47.
PRODRUGS OF (1S,9S)-9-[[(1S)-1-CARBOXY-3-PHENYLPROPYL]AMINO]OCTAHYDRO-10-OXO-6H-PYRIDAZINO[1,2-A][1,2]DIAZEPINE-1-CARBOXYLIC ACID AND THEIR USE IN TRANSDERMAL THERAPEUTIC SYSTEMS
The present invention relates to diester prodrugs of cilazaprilate which undergo enzymatic cleavage to release the active metabolite cilazaprilate that is used for the treatment of hypertension and congestive heart failure. Furthermore the diester prodrugs of cilazaprilate possess all the properties necessary to be topically administered, preferably via transdermal therapeutic systems.
A61K 47/48 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
The present invention is related to a pharmaceutical formulation comprising a biopharmaceutical drug, said composition further comprising at least one mono- or dicarboxylic acid with a backbone of 2-6 C-Atoms, or at least one salt thereof.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
49.
ADHESIVE COMPOSITION CONTAINING ROTIGOTINE AND TRANSDERMAL THERAPEUTIC SYSTEM COMPRISING THE ADHESIVE COMPOSITION
The present invention relates to an adhesive composition containing a pressure sensitive adhesive (PSA) selected from the group consisting of a styrenic polymer, a polyisobutylene, or mixtures thereof, rotigotine or a pharmaceutically acceptable salt thereof as the active !"ingredient, and at least one crosslinked polyvinyl pyrrolidone or at least one copolymer of vinyl pyrrolidone and vinyl acetate, or a mixture thereof. Moreover, the present invention relates to a transdermal therapeutic system (TTS) for the transdermal administration of rotigotine which comprises the adhesive composition. Further the present invention relates to a method for producing such a TTS and to a pouch comprising the TTS. In particular, the invention relates to the use of a transdermal therapeutic system for the purpose to treat or alleviate dopamine-related disorders such as Parkinson's Disease.
The present invention is directed to an orally disintegrating tablet having a taste masking effect, comprising at least one unpleasant-tasting pharmaceutically active ingredient having a particle size d (0.1) of 50 μm or more.
The invention is concerned with a transdermal therapeutic system (TTS) comprising buprenorphine and a method of manufacturing such a TTS. The transdermal therapeutic system is used for the transdermal administration of buprenorphine and analogues thereof. In particular, the invention relates to the use of a transdermal therapeutic system (TTS) for analgesic purposes. The TTS according to the invention comprises a transdermal drug delivery composition comprising buprenorphine and an adhesive component, which is a mixture of a crosslinked and a non-crosslinked acrylic polymer and a penetration enhancer comprising a keto acid.
Crystalline solifenacin succinate, the solifenacin succinate having an average axial ratio of 5:1 or less, preferably an average axial ratio of 5:1 to 1:1, more preferably an average axial ratio of 1:1, and having at least one of the following properties: a) a particle size d 0.9 < 200 μm; b) an average particle size of approximately 2 to 40 μm; and c) peaks in the X‑ray powder diffractogram at 3.7; 11.1; 18.6; 21.8° 2θ ± 0.2° 2θ.
C07D 453/02 - Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
A61K 31/472 - Non-condensed isoquinolines, e.g. papaverine
A61P 13/00 - Drugs for disorders of the urinary system
53.
ORAL PHARMACEUTICAL FILM FORMULATION FOR BITTER-TASTING DRUGS
The invention relates to a pharmaceutical film formulation comprising one or more bitter-tasting drug(s) or pharmaceutically acceptable salts thereof, one or more film formers, a bitterness masker containing one or more inorganic and/or organic salt(s) and at least two monocyclic monoterpenes, and one or more sweetening agent(s).
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
A61K 31/4045 - Indole-alkylaminesAmides thereof, e.g. serotonin, melatonin
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
The invention relates to a process for preparing a composition, more particularly a pharmaceutical composition for oral administration, comprising the steps of forming a suspension of at least one pharmaceutical ingredient and a solvent or solvent mixture, the at least one pharmaceutical ingredient being insoluble or poorly soluble in the solvent or solvent mixture, the step of adding at least one gel former to the suspension, the at least one gel former being swellable in the solvent or solvent mixture, and, optionally, the step of swelling the suspension.
The invention relates to a mucosal film which contains a pharmaceutical and a combination made of a first sugar substitute (Ζ1) and a second sugar substitute (Z2), wherein (Z1) and (Z2) are each 4- to 8-valent alcohols that are different from one another. The invention further relates to the production of said mucosal film and to a pharmaceutical product which contains one or more such mucosal films.
The present invention is related to an enhancer consisting of a monoester or diester of a hydroxy dicarboxylic acid, for use in the transdermal administration of a pharmaceutically active agent to a subject wherein the hydroxy dicarboxylic acid is of formula (I): R1OOC-(CHOH)x-(CH2)y- (CHOH)z -COOR2 wherein x and z are each and independently any integer from 0 to 5, whereby if x = z, x and z are≠ 0, preferably x is any integer from 1-5, more preferably x is 1 or 2, and z is 0; y is any integer form 0 to 10, preferably 1-5, most preferably 1; and R1 and R2 are each and independently a mixture of a branched C12 and C13 alcohol of formula (II) wherein m + n is either 8 or 9.
A61K 31/565 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
The present invention relates in general to the field of organic chemistry, and in particular to the preparation of phenyl derivatives comprising a (1H-1,2,4-triazol-1-yl)alkyl group such as anastrozole (2,2'-(5-((1H-1,2,4-triazol-1-yl)methyl)-1,3-phenylene) bis(2-methyl-propanenitrile).
The present invention relates in general to the field of organic chemistry, and in particular to the preparation of benzo[b]thiophene derivatives. These benzo[b]thiophene derivatives are useful as intermediates in the synthesis of pharmaceutically active agents such as raloxifene or derivatives thereof.
The present invention relates in general to the field of organic chemistry, and in particular to the preparation of benzo[b]thiophene derivatives. These benzo[b]thiophene derivatives are useful as intermediates in the synthesis of pharmaceutically active agents such as raloxifene or derivatives thereof.
C07D 333/56 - Radicals substituted by oxygen atoms
C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
C07C 303/26 - Preparation of esters or amides of sulfuric acidsPreparation of sulfonic acids or of their esters, halides, anhydrides or amides of esters of sulfonic acids
The present invention refers to a dosage form comprising an enteric coating in a specific amount, and to the use of enteric coating compositions for preparing a dosage form. Furthermore, the present invention also relates to a process for the preparation of a solid oral dosage form.
The present invention is directed to a tablet comprising at least one bitter tasting and/or mucosa numbness causing pharmaceutically active compound; and at least one zinc salt. In addition, the present invention relates to the use of a zinc salt to reduce or mask the bitter taste of or the numbness of the mucosa caused by pharmaceutically active compounds.
The present invention relates to a method of producing syringes. Said method comprises fixing a needle to a syringe body by use of an adhesive followed by subjecting the syringes thus obtained to heat treatment. The invention further relates to a method of reducing leachables and/or extractables in prefilled syringes, said method comprising heat treating pre-fabricated syringes at a temperature of at least 40°C before filling.
B65B 3/00 - Packaging plastic material, semiliquids, liquids or mixed solids and liquids, in individual containers or receptacles, e.g. bags, sacks, boxes, cartons, cans or jars
B65B 55/14 - Sterilising contents prior to, or during, packaging by heat
C09J 5/06 - Adhesive processes in generalAdhesive processes not provided for elsewhere, e.g. relating to primers involving heating of the applied adhesive
A61M 5/34 - Constructions for connecting the needle
The invention relates to a granulate comprising escitalopram oxalate having an average particle size of less than 100 μm and at least one filler. The invention further relates to a method of producing that granulate and also to a tablet or capsule comprising that granulate and/or obtained by compressing that granulate to form a tablet or by filling that granulate into a capsule shell. Finally, the invention relates to the use of that granulate and/or tablet or capsule in the treatment or prevention of a disorder from the spectrum of depressive disorders.
The present invention refers to compositions comprising a LH-RH-analogue and/or pharmaceutically acceptable salts thereof in a low-dose and a degradation-resistant polylactide suitable for the preparation of subcutaneous implants. Sterilisation of the polylactide via gamma-radiation as well as temperature stress result in a negligible decomposition of less than 1000 Dalton.
The invention relates to a process for preparing certain adamantanamines, of formula (IV) wherein R, R' are each methyl and X is halogen, to intermediates used in the process, and to processes for preparing such intermediates.
C07C 209/62 - Preparation of compounds containing amino groups bound to a carbon skeleton by cleaving carbon-to-nitrogen, sulfur-to-nitrogen, or phosphorus-to-nitrogen bonds, e.g. hydrolysis of amides, N-dealkylation of amines or quaternary ammonium compounds
C07C 211/38 - Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton containing condensed ring systems
C07C 233/06 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
C07C 335/32 - Isothioureas having sulfur atoms of isothiourea groups bound to acyclic carbon atoms
67.
MATRIX-CONTROLLED TRANSDERMAL SYSTEM COMPRISING SALTS OF ACE INHIBITOR DICARBOXYLIC ACIDS
The invention relates to a salt of an ACE inhibitor dicarboxylic acid comprising an organic amine and/or an alkali compound, a transdermal therapeutic system comprising said salt, and a method for producing the transdermal therapeutic system.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical, veterinary and sanitary preparations, dietetic substances adapted for medical use, food for babies, plasters, materials for dressings material for stopping teeth, dental wax disinfectants, preparations for destroying vermin; fungicides, herbicides.
69.
COMBINED PREPARATION OF A THIAZIDE DIURETIC AND A LOOP DIURETIC
The invention relates to pharmaceutical preparations which contain a combination of a thiazide diuretic and a low dose of a loop diuretic and which is particularly suitable for treating hypertension and heart failure. It is not only the natriuretic/diuretic effects which are increased due to said combination of thiazide diuretic and loop diuretic, but also the undesired secondary effects in relation to potassium and magnesium losses are also significantly reduced. As a result, the desired hypocalciuric effect of the thiazide is maintained despite the presence of the loop diuretic.
A61K 31/64 - Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
A61K 31/549 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
The invention relates to a method for producing an oxaliplatin aqueous solution consisting in diluting oxaliplatin by adding an acid in such a way that the oxaliplatin concentration greater than the concentration of the acid-free oxaliplatin aqueous solution is obtained. A container and a container set containing the inventive solution are also disclosed.
A61K 31/555 - Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
A61K 47/00 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient
A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
71.
CYCLOOLEFIN COPOLYMER BOTTLE WITH A SCRATCH-RESISTANT COATING
The invention relates to a bottle made from plastic, including or made from cycloolefin copolymer, with a coating of an inorganic/organic hybrid polymer (ORMOCER coating) .
The invention relates to a film-shaped, single-layered and cavity-free preparation that does not contain any surfactants nor effervescent additives and flavor masking agents, comprised of film forming agents, one or more gelling agents and of one or more active substances selected from the group of neuroleptic drugs.
A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
73.
ORAL, QUICKLY DISINTEGRATING FILM, WHICH CANNOT BE SPIT OUT, FOR AN ANTIEMETIC OR ANTIMIGRAINE AGENT
The invention relates to a film-shaped, single-layered and cavity-free preparation that does not contain any surfactants nor effervescent additives and flavor masking agents, comprised of film forming agents, one or more gelling agents and of one or more active substances selected from the group of antiemetics and antimigraine agents.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical, veterinary and sanitary preparations;
dietetic products adapted for medical use, food for babies;
plasters, materials for dressings; disinfectants.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; disinfectants; diagnostic preparations for pharmaceutical and veterinary purposes, in particular chemically or biologically manufactured, and/or genetically engineered products for medical diagnostic analysis; medical products included in class 5.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; disinfectants; diagnostic preparations for pharmaceutical and veterinary purposes, in particular chemically or biologically manufactured, and/or genetically engineered products for medical diagnostic analysis; medical products included in class 5.
05 - Pharmaceutical, veterinary and sanitary products
29 - Meat, dairy products, prepared or preserved foods
32 - Beers; non-alcoholic beverages
Goods & Services
Pharmaceutical, veterinary preparations; preparations for
heath care; dietetic substances adapted for medical use;
food supplements for medical purposes; preparations
containing vitamins, enzymes, minerals and/or trace
elements; plasters, materials for dressings; diagnostic
preparations and test kits for pharmaceutical, medical and
veterinary purposes; biological and/or genetically
engineered products for medical diagnostic analysis; medical
products included in this class. Dietetic foodstuffs and foods supplements not adapted for
medical use, included in this class. Dietary beverages and/or preparations for making beverages
for non medical purposes containing vitamins, enzymes,
minerals, trace elements, flavourings and/or flavour
enhancing substances and/or sweeteners, either individually
or in combination, included in this class.
03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Cosmetic and medicated soaps; perfumes; essential oils;
cosmetics; hair lotions; dentifrices. Pharmaceutical and veterinary preparations; sanitary
preparations for medical purposes; dietetic substances
adapted for medical use; food supplements adapted for
medical use; food for babies; preparations comprising
vitamins, enzymes, minerals and/or trace elements; plasters,
materials for dressings; disinfectants; diagnostic
preparations and test kits for pharmaceutical, medical and
veterinary use; preparations for a medico-diagnostic
analysis manufactured through biological methods and/or
methods of genetic engineering; medical products included in
this class.
01 - Chemical and biological materials for industrial, scientific and agricultural use
03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations
05 - Pharmaceutical, veterinary and sanitary products
07 - Machines and machine tools
09 - Scientific and electric apparatus and instruments
10 - Medical apparatus and instruments
11 - Environmental control apparatus
13 - Firearms; explosives
16 - Paper, cardboard and goods made from these materials
17 - Rubber and plastic; packing and insulating materials
22 - Rope, netting, tents, awnings, sails and sacks; padding and stuffing materials
29 - Meat, dairy products, prepared or preserved foods
31 - Agricultural products; live animals
Goods & Services
(1) Pharmaceutical, veterinary and sanitary preparations in the form of tablets, pills, capsulae, pellets, powders, granulates, drops, inhalation preparations, aerosols, suppositories, ointments, gels, lotions, solutions and plasters, namely urologics, preparations for reducing the weight, aldosterone antagonists, namely spironolactone, analeptics/antihypoxemics, analgetics/antirheumatics, anthelmintics, antiallergics, antianemics, antiarrhythmics, antibiotics, preparations for treating tumors and destroying pathogens, antidementives (nootropics), antidiabetics, antidota, antiemetics, preparations for treating dizziness, antiepileptics, antifibrinolytics, antihypertonics, antihypoglycemics, antihypotonics, anticoagulants, preparations for combatting parasites, antiphlogistics, preparations for counteracting and treating sclerosis, bath additives and agents for the heat therapy for treating dermatic allergic, metabolic, rheumatic, ischiatic and neuralgic diseases, diseases of the respiratory system and catarrhs, influenza, colds, weakness and states of exhaustion, lumbago, affections and diseases of the joints, muscles and intervertebral discs, namely rheumatism, arthrosis and arthritis or affections and diseases of the joints, muscles and intervertebral discs to be treated with diclofenac and ibuprofen; diseases of the movement system, namely rheumatism, arthrosis and arthritis, or diseases of the movement system to be treated with diclofenac and ibuprofen; diseases of the stomach and gallbladder, namely ulcer ventricular, ulcer duodenitis, peptic esophagitis, gastritis and helicobacter pylori eradication; bruises, contusions, pullings, sprains, fractures, distortions, insomnia, nervous disturbances, namely depression, schizophrenia, disorder of sleep, anxiety disorder or nervous disturbances to be treated with tranquilizers; disturbances of the circulation, namely hypertension, cardiac hypertrophy, dysrhytmica and coronary heart failure; roborants, low blood-pressure, wounds, traumula diseases of the spinal cord, renal diseases, diseases of the liver and ovary, gout, pemiosis, acrocyenosis, hyperhydrosis, hypertonicity, atheroslerosis, arthrosis, scrofulosis, adnexitis, gynecologic diseases, perametritis, endometritis, static disturbances, injuries caused by sport, tendoveginitis, myalgies, vasomotoric-trophic diseases, brachialgia, hematoma, frostbite, venous congestions, cervical, thoracal and lumbar syndrome, arthropathy, traumatic diseases, prostatitis, renal diseases, limbs distrophy, myogelosis, epicondylitis, diseases of the thyroid gland, namely hypothyroidism and hyperthyroidism; manager syndrome, beta-receptor blocking preparations for treating heart and circulation diseases and hypertension, calcium antagonists and angiotensin enzyme inhibitors, broncholytics/antiasthmatics, preparations for treating diseases of the gallbladder and of the gallbladder tract, preparations for treating diseases caused by the effect of acetylcholine, cortocoids, dermatics, preparations for disinfectant and antiseptic treatment of hands, skin, mucous membrane surfaces, wounds, vagina, cervix, urethra, bladder medical instruments, medical instruments, hospital instruments and objects, contact lenses, chemical toilets; dietetic and nutrition preparations for treating renal insufficiency, diuretics, preparations for treating insufficiency of the blood circulation, emetics, preparations for curing dependence on alcohol and tobacco, enzyme inhibitors, enzyme preparations and transport proteins, fibrinolytics, preparations for treating geriatric diseases, disturbances and insufficiencies namely arteriosclerosis, degenerative changes, namely arthrosis; decrease of the physical and mental tonus and vigour, indigestion, weak concentration, weak memory and weak nerves, activation of the mental and physical efficiency in the old age, against of lack of vitamins and mineral substances, for the regeneration of the exhausted organism, troubles of the old age, weak drive, tiredness, irritability, depressive ill-feeling, degenerative changes of the blood vessels, apoplexy, buzzing in the ears, growing old before one's time, physical and mental states of exhaustion, hardness of hearing related to old age, hardening of the arteries, rheumatic fever, sleeping disturbances, nervousness, cerebral deficiencies of circulation, weak circulation related to old age, reduced elasticity of the vessels, peripheric circulatory disturbances, pains in arthropathies and arthrosis, reduced skin elasticity, prophylaxis and therapy of deficiencies related to old age, physical and mental exhaustion, protection of liver, convalescence, infarction risk, intensification of the defence produced in the body to be treated with immunostimulantia, anemies, disturbances of the metabolism, namely diabetes mellitus, gout and hypercholesterolemia; supporting treatment of the heart insufficiency and dizziness; preparations for treating gout, preparations for treating grippal infections, influenza and cold diseases, preparations for treating gynecologic diseases, namely vaginal mycosis and fertility disorder, chemical defined contraceptives; preparations for treating hemorrhoids, hemostyptics/antihemorrhagics, hypnotics/sedatives, hypophysis and hypothalamus hormones, preparations containing other regulatory peptides or their inhibitors for treating diseases due to respective dysfunction namely acute bleeding of gastroduodenal ulcus, acute bleeding in case of erosive or haemorrhagic gastritis, prophylasix of postoperative pancreatic complications after pancreas surgery, adjuvant therapy for inhibiting the secretion of postoperative pancreas and upper small intestine fistulae symptom treatment of endocrinal active tumors of the gastrointestinal tract, metastasis carcinoids with the features of the carcinoid syndrome, such as flush and serious diarrheas, VIbomes with strong aqueous diarrheas, glucagonomes with inflammatory destruction of skin by necrolytic, migratoric erythema, symptom treatment and lowering of the plasma level of the growth hormone-(GH) and IGF-I in patients with acromegaly in whom a surgical treatment, radiotherapy or a treatment with a dopamin agonist did not result in a success, in patients who are not ready or are not in a position to undergo an operation or for bridging until the radiotherapy demonstrates its full effect; preparations for treating diseases of the immune system, namely human immunodeficiency virus, and zytokines, insufficiency of kidneys and heart to be treated with furosemide and torasemide, edema to be treated with hydrochlorothiazid, furosemide and torasemide, for decreasing the internal pressure in eyes and in the brain and for forced and osmotic diuresis, for treating diseases of deficiency of volume and of microcirculation and of plasma and for treating diseases of liver and heart and diabetes, organo perfusion solutions, preparations for treating heart diseases, preparations for treating caries and paradentosis, preparations for treating coronary diseases, preparations for treating liver diseases, laxatives, lipid-Iowering substances, preparations for locally anaesthetising for diminishing or avoiding pain and for treating neural dyafunctions, namely depression, schizophrenia, disorder of sleep, anxiety disorder or preparations for treating neutral dynafunctions to be treated with tranquilizers, preparations for treating migraine, preparations for treating diseases of the mouth and throat, muscle relaxants, narcotics, parathyroid gland hormones/therapeutics for regulating the calcium metabolism, preparations for treating neuropathy, namely to be treated with a-Iipoic acid and gabapentine, preparations for treating eye diseases, preparations for treating ear diseases, therapeutics for Parkinson's disease and against other extrapyramidal disturbances to be treated with carbamazepine, valproin acid and levodopa, rhinologics, thyroid gland therapeutics, sex hormones and their inhibitors, spasmolytics, sulfonamides, inhibitors of the aggregation of thrombozytes, preparations for treating tuberculosis, preparations for treating diseased organs and dysfunctions and for returning same to a state of normality to be treated with cyclosporines; preparations for treating tumors and cancer and for inhibiting metastases, preparations of bio materials and medical plastics for anchoring protheses; dietary supplements namely vitamins, minerals, lecithin, enzymes and/or trace- elements; food supplements namely vitamins, minerals, lecithin, enzymes and/or trace-elements; nutritional supplements namely vitamins, minerals, lecithin, enzymes and/or trade-elements; plaster, materials for dressing; diagnostic preparations and test kits for pharmaceutical, medical and veterinary use.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical and veterinary preparations; preparations for health care; plasters, materials for dressings; diagnostic preparations and test kits for pharmaceutical, medical and veterinary purposes; biological and/or genetically engineered products for medical and diagnostic analysis; medical products included in class 05.
05 - Pharmaceutical, veterinary and sanitary products
29 - Meat, dairy products, prepared or preserved foods
32 - Beers; non-alcoholic beverages
Goods & Services
Pharmaceutical and veterinary preparations; preparations for health care; dietetic substances adapted for medical use; food supplements for medical purposes; preparations containing vitamins, enzymes, minerals and/or trace elements; plasters, materials for dressings; diagnostic preparations and test kits for pharmaceutical, medical and veterinary purposes; biological and/or genetically engineered products for medical and diagnostic analysis; medical products included in class 5. Dietetic foodstuffs and food supplements not adapted for medical use, included in class 29. Dietary foods and food supplements for non-medical purposes in the form of beverages and/or preparations for making beverages based on and/or consisting of vitamins, enzymes, minerals, trace elements, flavourings and/or flavour-enhancing substances and/or sweeteners, either individually or in combination, included in class 32.
03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations
05 - Pharmaceutical, veterinary and sanitary products
09 - Scientific and electric apparatus and instruments
10 - Medical apparatus and instruments
16 - Paper, cardboard and goods made from these materials
29 - Meat, dairy products, prepared or preserved foods
30 - Basic staples, tea, coffee, baked goods and confectionery
32 - Beers; non-alcoholic beverages
38 - Telecommunications services
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
Goods & Services
Soaps; perfums; essential oils; cosmetics; hair lotions; dentifrices. Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use; food supplements adapted for medical use; food for babies; preparations comprising vitamins, enzymes, minerals and/or trace elements; plasters, materials for dressings; disinfectants; diagnostic preparations and test kits for pharmaceutical, medical and veterinary use; preparations for a medico-diagnostic analysis manufactured through biological methods and/or methods of genetic engineering; medical products as far as contained in class 5. Electrical, electronic, optical, acoustic apparatus and instruments; apparatus and instruments for recording, storing, processing, transmitting and reproducing sound, images and/or data; teaching and instructing apparatus and instruments as far as contained in class 9; carriers for optical, acoustic or electronic data, provided with data or not, in the form of films, boards, magnetic tapes, floppy discs, discs, CD-ROMs, DVDs; software, data processing programs. Surgical, medical, dental or veterinary apparatus and instruments; prostheses, artificial limbs, eyes and teeth; orthopedic articles; surgical suture materials; medical products as far as contained in class 10; contraceptives, non-chemical. Printed matter; medical, pharmacological and pharmaceutical encyclopediac; medical, pharmacological and pharmaceutical textbooks; health care encyclopediae; medical advisory textbooks; pharmaceutical advisory textbooks; product descriptions; application manuals, also for software. Dietetic food and food supplements adapted for non-medical use, as far as contained in class 29. Dietetic food and food supplements adapted for non-medical use, as far as contained in class 30. Dietetic food and food supplements adapted for non-medical use in the form of drinks and/or preparations for preparing drinks based on and/or consisting of vitamins, enzymes, minerals, trace elements, aromas, flavours and/or sweeteners, either singly or in combination, as far as contained in class 32. Installing or maintaining of web-sites, particularly providing medical, pharmaceutical and/or health information; Internet services connected to collecting, processing, reproducing and providing news and information, particularly on medical, pharmaceutical and/or health issues; storing, processing and/or transmitting information on medical, pharmaceutical and/or health issues via local, regional, national and/or global networks. Conducting and organising events for education, training or continued education, particularly of medical practitioners, pharmaceutical practitioners and/or employees in the medical, pharmaceutical and/or health fields; planning, organising and conducting conventions, symposia and meetings in the medical, pharmaceutical and/or health fields; conducting and organising correspondence courses; sponsoring of cultural or sports events. Consultation and services in the pharmaceutical, pharmacological, medical and veterinary fields as well as in the sanitary field; technical advice for third parties in the fields of distribution, manufacture and/or development of pharmaceutical and veterinary products as well as in the fields of construction and operation of plants for the production of pharmaceutical and veterinary products; scientific research; drafting and operating of data processing programs and network data base systems; computer programming.
03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations
05 - Pharmaceutical, veterinary and sanitary products
29 - Meat, dairy products, prepared or preserved foods
30 - Basic staples, tea, coffee, baked goods and confectionery
Goods & Services
Savons; parfumerie, huiles essentielles, cosmétiques,
lotions pour les cheveux; dentifrices. Produits pharmaceutiques, vétérinaires et hygiéniques;
substances diététiques à usage médical, aliments pour bébés;
emplâtres, matériel pour pansements; matières pour plomber
les dents et pour empreintes dentaires; désinfectants;
produits pour la destruction des animaux nuisibles;
fongicides, herbicides; aliments diététiques et/ou
compléments alimentaires à usage non médical à base de/ou
composés de substances de lest, ou seuls ou en combinaison
avec des hydrates de carbone, le cas échéant, en ajoutant
des vitamines, des enzymes, des substances minérales, des
oligo-éléments, des substances d'arômes et/ou aromates, des
édulcorants, ou seuls ou en combinaison, compris dans cette
classe. Aliments diététiques et/ou compléments alimentaires à usage
non médical à base de/ou composés de protéines, de graisses,
d'acides gras, ou seuls ou en combinaison, le cas échéant en
ajoutant des vitamines, des enzymes, des substances
minérales, des oligo-éléments, des substances d'arômes et/ou
aromates, des édulcorants, ou seuls ou en combinaison,
compris dans cette classe. Aliments diététiques et/ou compléments alimentaires à usage
non médical à base de/ou composés d'hydrates de carbone, ou
seuls ou en combinaison avec des substances de lest, le cas
échéant en ajoutant des vitamines, des enzymes, des
substances minérales, des oligo-éléments, des substances
d'arôme et/ou des aromates, des édulcorants, ou seuls ou en
combinaison, compris dans cette classe.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Produits pharmaceutiques, vétérinaires et hygiéniques;
substances diététiques à usage médical, aliments pour bébés;
emplâtres, matériel pour pansements; matières pour plomber
les dents et pour empreintes dentaires; désinfectants.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Médicaments, produits chimiques pour la médecine et
l'hygiène, drogues et préparations pharmaceutiques,
emplâtres, étoffes pour pansements, produits pour la
destruction d'animaux et de végétaux, désinfectants.
